O
GPCR icon

OrbiMed’s Structure Therapeutics GPCR Stock Holding History

OrbiMed’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-150,000
Closed -$2.6M – 107
2025
Q1 		$2.6M Hold
150,000
– – 0.06% 88
2024
Q4 		$4.07M Buy
+150,000
New +$5.32M 0.08% 91

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

OrbiMed's GPCR Position: Q1 2026 in Review

OrbiMed increased its Structure Therapeutics (GPCR) stake by 27% in Q1 2026, buying an estimated $21.5M and bringing the position to 1,475,403 shares worth $71.1M. The position accounts for 1.41% of the portfolio, ranked #18.

OrbiMed first reported a position in GPCR in Q2 2024 and has held it in 8 quarters since. The position peaked at $80.8M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • OrbiMed held 1,475,403 shares of Structure Therapeutics worth $71.1M as of Q1 2026.
  • OrbiMed bought 313,600 Structure Therapeutics shares in Q1 2026, an estimated $21.5M.
  • Structure Therapeutics made up 1.41% of OrbiMed's portfolio in Q1 2026, its #18 holding.
  • OrbiMed first reported a position in Structure Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • OrbiMed's Structure Therapeutics position peaked at $80.8M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.